

Edgar Filing: RadNet, Inc. - Form 10-Q

RadNet, Inc.
Form 10-Q
November 14, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2007

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 0-19019

RADNET, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

NEW YORK
(STATE OR OTHER JURISDICTION OF
INCORPORATION OR ORGANIZATION)

13-3326724
(I.R.S. EMPLOYER
IDENTIFICATION NO.)

1510 COTNER AVENUE
LOS ANGELES, CALIFORNIA
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

90025
(ZIP CODE)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (310) 478-7808

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities and Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

--- ---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☒

Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2) Yes ☐ No ☒

--- ---

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and

Edgar Filing: RadNet, Inc. - Form 10-Q

reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes X No
--- ---

The number of shares of the registrant's common stock outstanding on November 10, 2007, was 34,789,558 shares (excluding treasury shares).

1

Table of Contents

RADNET, INC.

INDEX

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Consolidated Balance Sheets at September 30, 2007 (unaudited) and December 31, 2006

Consolidated Statements of Operations (unaudited) for the Three and Nine Months ended September 30, 2007 and 2006

Consolidated Statement of Stockholders' Deficit (unaudited) for the Nine Months ended September 30, 2007

Consolidated Statements of Cash Flows (unaudited) for the Nine Months Ended September 30, 2007 and 2006

Notes to Consolidated Financial Statements

ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

ITEM 3. Quantitative and Qualitative Disclosures About Market Risk

ITEM 4. Controls and Procedures

PART II - OTHER INFORMATION

ITEM 1 Legal Proceedings

ITEM 1A. Risk Factors

ITEM 6 Exhibits

SIGNATURES

INDEX TO EXHIBITS

2

PART 1 - FINANCIAL INFORMATION

Edgar Filing: RadNet, Inc. - Form 10-Q

Item 1. Financial Statements

| RADNET, INC. AND SUBSIDIARIES | | |
|--|-----------------------|----------------------|
| CONSOLIDATED BALANCE SHEETS | | |
| (IN THOUSANDS EXCEPT PER SHARE DATA) | | |
| | September 30, 2007 | December 31, 2006 |
| | ----- (Unaudited) | ----- |
| ASSETS | | |
| CURRENT ASSETS | | |
| Cash and cash equivalents | \$ -- | \$ 3,221 |
| Restricted cash | 6,909 | -- |
| Accounts receivable, net | 92,662 | 70,794 |
| Due from affiliates | -- | 1,427 |
| Refundable income taxes | 105 | 6,464 |
| Other current assets | 9,115 | 7,518 |
| | ----- | ----- |
| Total current assets | 108,791 | 89,424 |
| PROPERTY AND EQUIPMENT, NET | 160,186 | 158,542 |
| OTHER ASSETS | | |
| Goodwill | 83,476 | 61,607 |
| Other intangible assets, net | 58,961 | 60,484 |
| Deferred financing cost, net | 9,160 | 9,422 |
| Investment in joint ventures | 9,633 | 10,125 |
| Trade name and other | 3,758 | 4,751 |
| | ----- | ----- |
| Total other assets | 164,988 | 146,389 |
| | ----- | ----- |
| Total assets | \$ 433,965 | \$ 394,355 |
| | ===== | ===== |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | | |
| CURRENT LIABILITIES | | |
| Accounts payable | \$ 13,610 | \$ 23,038 |
| Accrued expenses | 41,295 | 26,854 |
| Notes payable | 3,066 | 2,969 |
| Current portion of deferred rent | 331 | 559 |
| Due to affiliates | 323 | -- |
| Obligations under capital leases | 9,361 | 4,626 |
| | ----- | ----- |
| Total current liabilities | 67,986 | 58,046 |
| | ----- | ----- |
| LONG-TERM LIABILITIES | | |
| Line of credit | -- | 22 |
| Notes payable, net of current portion | 382,230 | 360,083 |
| Obligations under capital lease, net of current portio | 23,109 | 11,305 |
| Deferred rent, net of current portion | 5,248 | 991 |
| Other non-current liabilities | 8,464 | 9,650 |
| | ----- | ----- |
| Total long-term liabilities | 419,051 | 382,051 |
| | ----- | ----- |
| COMMITMENTS AND CONTINGENCIES | | |
| MINORITY INTERESTS | 997 | 1,254 |
| STOCKHOLDERS' DEFICIT | | |

Edgar Filing: RadNet, Inc. - Form 10-Q

| | | |
|--|------------|------------|
| Preferred stock - \$.0001 par value, 30,000,000 shares authorized, none issued | -- | -- |
| Common stock - \$.0001 par value, 200,000,000 shares authorized; 34,789,558 and 34,973,780 shares issued at September 30, 2007 and December 31, 2006, respectively; 34,789,558 and 34,061,281 shares outstanding at September 30, 2007 and December 31, 2006, respectively | 4 | 3 |
| Paid-in-capital | 148,793 | 146,056 |
| Accumulated other comprehensive loss | (1,819) | (73) |
| Accumulated deficit | (201,047) | (192,287) |
| | ----- | ----- |
| | (54,069) | (46,301) |
| Less: Treasury stock - 912,500 shares at cost | -- | (695) |
| | ----- | ----- |
| Total stockholders' deficit | (54,069) | (46,996) |
| | ----- | ----- |
| Total liabilities and stockholders' deficit | \$ 433,965 | \$ 394,355 |
| | ===== | ===== |

The accompanying notes are an integral part of these financial statements.

3

RADNET, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (IN THOUSANDS EXCEPT PER SHARE DATA)

| | THREE MONTHS ENDED SEPTEMBER 30, | | NINE MONTHS SEPTEMBER |
|----------------------------------|-------------------------------------|-----------|--------------------------|
| | 2007 | 2006 | 2007 |
| | ----- | ----- | ----- |
| NET REVENUE | \$ 110,209 | \$ 40,038 | \$ 323,051 |
| OPERATING EXPENSES | | | |
| Operating expenses | 83,503 | 30,323 | 244,405 |
| Depreciation and amortization | 11,405 | 4,131 | 32,495 |
| Provision for bad debts | 6,395 | 1,697 | 20,810 |
| Loss on sale of equipment | (4) | 305 | -- |
| Severance costs | 30 | -- | 815 |
| | ----- | ----- | ----- |
| Total operating expenses | 101,329 | 36,456 | 298,525 |
| | ----- | ----- | ----- |
| INCOME FROM OPERATIONS | 8,880 | 3,582 | 24,526 |
| OTHER EXPENSES (INCOME) | | | |
| Interest expense | 11,675 | 6,135 | 32,449 |
| Loss on debt extinguishment, net | -- | (21) | -- |
| Other expense (income) | (21) | 28 | (72) |
| | ----- | ----- | ----- |
| Total other expense | 11,654 | 6,142 | 32,377 |
| | ----- | ----- | ----- |

Edgar Filing: RadNet, Inc. - Form 10-Q

| | | | |
|--|------------|------------|------------|
| LOSS BEFORE INCOME TAXES, MINORITY INTEREST AND EARNINGS FROM JOINT VENTURES | (2,774) | (2,560) | (7,851) |
| Provision for income taxes | (86) | -- | (115) |
| Minority interest in income of subsidiaries | (198) | -- | (483) |
| Earnings from joint ventures | 1,103 | 83 | 3,080 |
| | ----- | ----- | ----- |
| NET LOSS | \$ (1,955) | \$ (2,477) | \$ (5,369) |
| | ===== | ===== | ===== |
| BASIC AND DILUTED NET LOSS PER SHARE | \$ (0.06) | \$ (0.12) | \$ (0.16) |
| | ===== | ===== | ===== |
| WEIGHTED AVERAGE SHARES OUTSTANDING: | | | |
| Basic and diluted | 34,749 | 21,238 | 34,567 |

The accompanying notes are an integral part of these financial statements.

4

RADNET, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF STOCKHOLDERS' DEFICIT NINE MONTHS ENDED SEPTEMBER 30, 2007 (IN THOUSANDS EXCEPT PER SHARE DATA)

| | | | |
|--|---|--------|-----------------|
| | Common Stock \$.0001 par value, 200,000,000 shares authorized | | |
| | ----- | ----- | Paid-in Capital |
| | Shares | Amount | ----- |
| | ----- | ----- | |
| BALANCE - DECEMBER 31, 2006 | 34,973,780 | \$ 3 | \$ 146,056 |
| Cumulative effect adjustment pursuant to adoption of SAB No. 108 | -- | -- | -- |
| Issuance of common stock upon exercise of stock options | 728,278 | 1 | 549 |
| Retirement of treasury shares | (912,500) | -- | (695) |
| Share-based payments | -- | 2,883 | -- |
| Change in fair value of cash flow hedging | -- | -- | -- |
| Net loss | -- | -- | -- |
| | ----- | ----- | ----- |
| BALANCE - SEPTEMBER 30, 2007 (UNAUDITED) | 34,789,558 | \$ 4 | \$ 148,793 |
| | ===== | ===== | ===== |

[table continued]

| | | |
|---------------------|---|-----------------------------|
| Accumulated Deficit | Accumulated Other Comprehensive Income (loss) | Total Stockholders' Deficit |
|---------------------|---|-----------------------------|

Edgar Filing: RadNet, Inc. - Form 10-Q

| | ----- | ----- | ----- |
|--|--------------|------------|-------------|
| BALANCE - DECEMBER 31, 2006 | \$ (192,287) | \$ (73) | \$ (46,996) |
| Cumulative effect adjustment pursuant to adoption of SAB No. 108 | (3,391) | -- | (3,391) |
| Issuance of common stock upon exercise of stock options | -- | -- | 550 |
| Retirement of treasury shares | -- | -- | -- |
| Share-based payments | -- | 2,883 | |
| Change in fair value of cash flow hedging | -- | (1,746) | (1,746) |
| Net loss | (5,369) | -- | (5,369) |
| | ----- | ----- | ----- |
| BALANCE - SEPTEMBER 30, 2007 (UNAUDITED) | \$ (201,047) | \$ (1,819) | \$ (54,069) |
| | ===== | ===== | ===== |

The accompanying notes are an integral part of these financial statements.

5

RADNET, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(IN THOUSANDS)

| | NINE MONTHS ENDED SEPTEMBER 30, | |
|---|------------------------------------|------------|
| | 2007 | 2006 |
| | ----- | ----- |
| CASH FLOWS FROM OPERATING ACTIVITIES | | |
| Net loss | \$ (5,369) | \$ (5,988) |
| Adjustments to reconcile net loss to net cash flows provided by operating activities: | | |
| Depreciation and amortization | 32,495 | 12,186 |
| Provision for bad debts and allowance adjustments | 20,810 | 5,022 |
| Minority interests in income of subsidiaries | 483 | -- |
| Distributions to minority interests | (740) | -- |
| Equity in earnings of joint ventures | (3,080) | (83) |
| Distributions from joint ventures | 3,572 | -- |
| Deferred rent | 638 | -- |
| Amortization of deferred financing cost | 1,428 | -- |
| Net loss on disposal of assets | -- | 373 |
| Loss on extinguishment of debt | -- | 2,097 |
| Employee stock compensation | 2,883 | 392 |
| Deferred revenue from sale of building | -- | (60) |
| Changes in operating assets and liabilities, net of assets acquired and liabilities assumed in purchase transactions: | | |
| Accounts receivable | (40,776) | (8,897) |
| Refundable income taxes | 6,359 | -- |
| Other current assets | (1,478) | (1,035) |
| Other assets | 1,815 | (314) |
| Accounts payable and accrued expenses | 1,660 | 4,047 |
| | ----- | ----- |

Edgar Filing: RadNet, Inc. - Form 10-Q

| | | |
|--|-----------|-----------|
| Net cash provided by operating activities | 20,700 | 7,740 |
| | ----- | ----- |
| CASH FLOWS FROM INVESTING ACTIVITIES | | |
| Purchase of imaging facilities | (15,665) | (3,388) |
| Purchase of property and equipment | (19,439) | (7,488) |
| Purchase of Radiologix | (370) | -- |
| Proceeds from sale of imaging facility | 1,300 | -- |
| Purchase of covenant not to compete contract | (250) | -- |
| Payments collected on notes receivable | 111 | -- |
| | ----- | ----- |
| Net cash used in investing activities | (34,313) | (10,876) |
| | ----- | ----- |
| CASH FLOWS FROM FINANCING ACTIVITIES | | |
| Principal payments on notes and leases payable | (7,159) | (3,429) |
| Repayment of debt upon extinguishments | -- | (141,243) |
| Proceeds from borrowings upon refinancing | -- | 146,468 |
| Debt issue costs | (1,167) | (5,608) |
| Change in restricted cash | (6,909) | -- |
| Proceeds from borrowings on notes payable & revolving credit | 28,865 | 5,495 |
| Payments on line of credit | (3,787) | -- |
| Proceeds from issuance of common stock | 549 | 1,453 |
| | ----- | ----- |
| Net cash generated from financing activities | 10,392 | 3,136 |
| | ----- | ----- |
| NET DECREASE IN CASH | (3,221) | -- |
| CASH, BEGINNING OF PERIOD | 3,221 | 2 |
| | ----- | ----- |
| CASH, END OF PERIOD | \$ -- | \$ 2 |
| | ===== | ===== |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | | |
| Cash paid during the period for interest | \$ 30,953 | \$ 11,331 |

The accompanying notes are an integral part of these financial statements.

RADNET, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (CONTINUED) FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2007 AND 2006

SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES

We entered into capital leases for approximately \$16.6 million and \$3.6 million for the nine months ended September 30, 2007 and 2006, respectively.

Edgar Filing: RadNet, Inc. - Form 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 - NATURE OF BUSINESS AND BASIS OF PRESENTATION

RadNet, Inc. or RadNet (formerly Primedex Health Systems, Inc.), was incorporated on October 21, 1985. Since our acquisition of Radiologix on November 15, 2006, we have operated a group of regional networks comprised of 143 diagnostic imaging facilities located in seven states with operations primarily in California, the Mid-Atlantic, the Treasure Coast area of Florida, Kansas and the Finger Lakes (Rochester) and Hudson Valley areas of New York, providing diagnostic imaging services including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology, or X-ray, and fluoroscopy. The Company's operations comprise a single segment for financial reporting purposes.

The results of operations of Radiologix and its wholly-owned subsidiaries have been included in the consolidated financial statements from the date of acquisition. The consolidated financial statements also include the accounts of Radnet Management, Inc., or RadNet Management, and Beverly Radiology Medical Group III (BRMG), which is a professional partnership, all collectively referred to as "us" or "we". The consolidated financial statements also include Radnet Sub, Inc., Radnet Management I, Inc., Radnet Management II, Inc., SoCal MR Site Management, Inc., and Diagnostic Imaging Services, Inc. (DIS), all wholly owned subsidiaries of RadNet Management.

Howard G. Berger, M.D. is our President and Chief Executive Officer, a member of our Board of Directors and owns approximately 17% of our outstanding common stock. Dr. Berger also owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at 52 of our facilities located in California under a management agreement with us, and contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California's prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. At eleven former Radiologix centers in California and at all of the former Radiologix centers which are located outside of California, we have entered into long-term contracts with prominent radiology groups in the area to provide physician services at those facilities. The operations of BRMG are consolidated with us as a result of the contractual and operational relationship among BRMG, Dr. Berger, and us. We are considered to have a controlling financial interest in BRMG pursuant to the guidance in Emerging Issues Task Force Issue 97-2 (EITF 97-2). BRMG is a partnership of Pronet Imaging Medical Group, Inc. and Beverly Radiology Medical Group, both of which are 99%-owned by Dr. Berger. RadNet provides non-medical, technical and administrative services to BRMG for which it receives a management fee.

Radiologix, our wholly-owned subsidiary, contracts with radiology practices to provide professional services, including supervision and interpretation of diagnostic imaging procedures, in its diagnostic imaging centers. The radiology practices maintain full control over the provision of professional radiological services. The contracted radiology practices generally have outstanding physician and practice credentials and reputations; strong competitive market positions; a broad sub-specialty mix of physicians; a history of growth and potential for continued growth.

Edgar Filing: RadNet, Inc. - Form 10-Q

Radiologix enters into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, it provides management services and receives a fee based on the practice group's professional revenue, including revenue derived outside of its diagnostic imaging centers. Radiologix owns the diagnostic imaging assets and, therefore, receives 100% of the technical reimbursements associated with imaging procedures. Radiologix has no financial controlling interest in the contracted radiology practices, as defined in EITF 97-2; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.

The accompanying unaudited consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X and, therefore, do not include all information and footnotes necessary for a fair presentation of financial position, results of operations and cash flows in conformity with accounting principles generally accepted in the United States for complete financial statements; however, in the opinion of our management, all adjustments consisting of normal recurring adjustments necessary for a fair presentation of financial position, results of operations and cash flows for the interim periods ended September 30, 2007 and 2006 have been made. The results of operations for any interim period are not necessarily indicative of the results for a full year. These interim consolidated financial statements should be read in conjunction with the

8

consolidated financial statements and related notes thereto contained in our Annual Report on Form 10-K for the year ended October 31, 2006 and our transition report on Form 10-K/T for the two months ended December 31, 2006.

Certain prior period amounts have been reclassified to conform to the current period presentation. These changes have no effect on net income.

LIQUIDITY AND CAPITAL RESOURCES

We had a working capital balance of \$40.8 million at September 30, 2007 compared to \$31.4 million at December 31, 2006, and a net loss of \$2.0 million and \$5.4 million during the three and nine months ended September 30, 2007, respectively. We also had a stockholders' deficit of \$54.1 million at September 30, 2007 compared to \$47.0 million at December 31, 2006.

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require significant amounts of capital for the initial start-up and development expense of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment, and to service our existing debt and contractual obligations. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

Our business strategy with regard to operations will focus on the following:

- |X| Maximizing performance at our existing facilities;
- |X| Focusing on profitable contracting;
- |X| Expanding MRI, CT and PET applications; |X| Optimizing operating efficiencies; and

Edgar Filing: RadNet, Inc. - Form 10-Q

|X| Expanding our networks

Our ability to generate sufficient cash flow from operations to make payments on our debt and other contractual obligations will depend on our future financial performance. A range of economic, competitive, regulatory, legislative and business factors, many of which are outside of our control, will affect our financial performance. Taking these factors into account, including our historical experience and our discussions with our lenders to date, although no assurance can be given, we believe that through implementing our strategic plans and continuing to restructure our financial obligations, we will obtain sufficient cash to satisfy our obligations as they become due in the next twelve months.

NOTE 2 - BUSINESS ACQUISITION

On November 15, 2006, we completed our acquisition of Radiologix, Inc. as a stock purchase. Under the terms of the merger agreement, Radiologix shareholders received aggregate consideration of 11,310,950 shares (or 22,621,900 shares before the one-for-two reverse stock split effected in late November 2006) of our common stock and \$42,950,000 in cash.

The total purchase price and the allocation of the estimated purchase price discussed below are preliminary and have not been finalized. The preliminary estimated total purchase price of the merger is as follows:

| | (IN THOUSANDS) |
|---|----------------|
| | ----- |
| Value of stock given by RadNet to Radiologix* | \$39,400 |
| Cash | 42,950 |
| Estimated transaction fees and expenses** | 15,208 |
| | ----- |
| Total purchase price | \$97,558 |
| | ===== |

(*) Calculated as 11,310,950 shares multiplied by \$3.48 (average closing price of \$1.74 from June 28, 2006 to July 13, 2006, adjusted for the one-for-two reverse stock split).

(**) Includes \$8,274,000 in assumed liabilities of Radiologix, including \$3,210,000 in merger and acquisition fees and \$5,064,000 in Radiologix bond prepayment penalties.

Under the purchase method of accounting, the total estimated purchase price as shown above and based on our consultation with an external valuation expert is allocated to Radiologix's net tangible and intangible assets based on their estimated fair values as of the date of acquisition. The following table summarizes the preliminary purchase price allocation at the date of acquisition.

9

| | (IN THOUSANDS) |
|--------------------------------|----------------|
| | ----- |
| Current assets | \$ 114,764 |
| Property and equipment, net | 78,173 |
| Identifiable intangible assets | 61,000 |
| Goodwill | 47,956 |
| Investments in joint ventures | 9,482 |
| Other assets | 974 |
| Current liabilities | (25,191) |
| Accrued restructuring charges | (314) |

Edgar Filing: RadNet, Inc. - Form 10-Q

| | |
|---|-----------|
| Contracts | (8,994) |
| Assumption of debt | (177,358) |
| Long-term liabilities | (1,725) |
| Minority interests in consolidated subsidiaries | (1,209) |
| | ----- |
| Total purchase price | \$ 97,558 |
| | ===== |

CASH, MARKETABLE SECURITIES, INVESTMENTS AND OTHER ASSETS: We valued cash, marketable securities, investments and other assets at their respective carrying amounts as we believe that these amounts approximated their current fair values.

IDENTIFIABLE INTANGIBLE ASSETS: Identifiable intangible assets acquired include management service agreements and covenants not to compete. Management service agreements represent the underlying relationships and agreements with certain professional radiology groups. Covenants not to compete are contracts entered into with certain former members of management of Radiologix on the date of acquisition.

Identifiable intangible assets consist of:

| (IN THOUSANDS) | ESTIMATED FAIR VALUE | ESTIMATED AMORTIZATION PERIOD | ANNUAL AMORTIZATION |
|-------------------------------|-------------------------|-------------------------------------|------------------------|
| ----- | ----- | ----- | ----- |
| Management service agreements | \$57,880 | 25 years | \$ 2,315 |
| Covenants not to compete | 3,120 | 1 to 2 years | 1,810 |

Estimated useful lives for the intangible assets were based on the average contract terms, which are greater than the amortization period that will be used for management contracts. Intangible assets are being amortized using the straight-line method, considering the pattern in which the economic benefits of the intangible assets are consumed.

GOODWILL: Approximately \$47,956,000 has been allocated to goodwill. This is an increase of approximately \$5.6 million from our estimate at June 30, 2007 based on a further refinement of our purchase price allocation. This amount may change when we finalize our estimate. The increase in goodwill includes a \$4.9 million decrease to property and equipment and a \$692,000 increase to accrued liabilities. Goodwill represents the excess of the purchase price over the fair value of the underlying net tangible and identifiable intangible assets. In accordance with SFAS No. 142, "Goodwill and Other Intangible Assets" goodwill will not be amortized but instead will be tested for impairment at least annually. We perform this test annually on December 1. In the event that management determines that the value of goodwill has become impaired, we will incur an accounting charge for the amount of impairment during the fiscal quarter in which the determination is made, which would normally be the fourth quarter. Because this goodwill was established through a stock purchase, no amount is deductible for tax purposes.

OPERATING LEASES: We assumed certain operating leases for both equipment and facilities. All related historical deferred rent liabilities have been eliminated. The establishment of any assets or liabilities associated with the Company's assumption of these operating leases is contingent upon final analysis from our external valuation experts.

Edgar Filing: RadNet, Inc. - Form 10-Q

NOTE 3 - FACILITY ACQUISITIONS AND DIVESTITURES

In September 2007, we acquired the assets and business of Walnut Creek Open MRI located in Walnut Creek, CA for \$225,000. The center provides MRI services. The leased facility associated with this center includes a monthly rental of approximately \$6,800 per month. Approximately \$50,000 of goodwill was recorded with respect to this transaction.

In September 2007, we acquired the assets and business of three facilities comprising of Valley Imaging Center, Inc. located in Victorville, CA for \$3.3 million in cash plus the assumption of approximately \$866,000 of debt. The acquired centers offer a combination of MRI, CT, X-ray, Mammography, Fluoroscopy and Ultrasound. The physician who provided the interpretive radiology services to these three locations joined BRMG. The leased facilities associated with these centers includes a total monthly rental of approximately \$18,000. Approximately \$2.8 million of goodwill was recorded with respect to this transaction.

In July 2007, we acquired the assets and business of Borg Imaging Group located in Rochester, NY for \$11.7 million in cash plus the assumption of approximately \$2.4 million of debt. Borg was the owner and operator of six imaging centers, five of which are multimodality, offering a combination of MRI, CT, X-ray, Mammography, Fluoroscopy and Ultrasound. After combining the Borg centers with RadNet's existing centers in Rochester, New York, RadNet has a total of 11 imaging centers in Rochester. The leased facilities associated with these centers includes a total monthly rental of approximately \$71,000 per month. Approximately \$9.2 million of goodwill was recorded with respect to this transaction.

In March 2007, we acquired the assets and business of Rockville Open MRI, located in Rockville, Maryland, for \$540,000 in cash and the assumption of a capital lease of \$1.1 million. The center provides MRI services. The center is 3,500 square feet with a monthly rental of approximately \$8,400 per month. Approximately \$365,000 of goodwill was recorded with respect to this transaction.

Our allocation of the purchase price with respect to our 2007 acquisitions to the fair value of the assets acquired and liabilities assumed is preliminary and subject to change upon completion of our allocation analysis.

In June 2007 we divested a non-course center in Duluth, Minnesota to a local multi-center operator for \$1.3 million. This was the only facility that we operated in Minnesota.

NOTE 4 - ADOPTION OF RECENT ACCOUNTING STANDARDS AND PRONOUNCEMENTS

In September 2006, the SEC issued Staff Accounting Bulletin No. 108 ("SAB No. 108"), "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements." SAB No. 108 specifies how the carryover or reversal of prior year unrecorded financial statement misstatements should be considered in quantifying a current year misstatement. SAB No. 108 requires an approach that considers the amount by which the current year Consolidated Statement of Operations is misstated ("rollover approach") and an approach that considers the cumulative amount by which the current year Consolidated Balance Sheet is misstated ("iron curtain approach").

Prior to the issuance of SAB No. 108, either the rollover or iron curtain approach was acceptable for assessing the materiality of financial statement misstatements. Prior to the Company's application of the guidance in

Edgar Filing: RadNet, Inc. - Form 10-Q

SAB No. 108, management used the rollover approach for quantifying financial statement misstatements.

Initial application of SAB No. 108 allows registrants to elect not to restate prior periods but to reflect the initial application in their annual financial statements covering the first fiscal year ending after November 15, 2006. The cumulative effect of the initial application should be reported in the carrying amounts of assets and liabilities as of the beginning of that fiscal year and the offsetting adjustment, net of tax, should be made to the opening balance of retained earnings for that year. We elected to record the effects of applying SAB No. 108 using the cumulative effect transition method. The misstatement that has been corrected is described below.

Subsequent to the completion of the financial statement close process for the three and six months ended June 30, 2007, we determined that certain lease rate escalation clauses had not been properly accounted for in accordance with generally accepted accounting principles for the fiscal years ended October 31, 2004, 2005 and 2006 as well as for the two months ended December 31, 2006 (our transition period) and for the quarter ended March 31, 2007. The Company had been recording rent expense based on the contractual terms of the lease agreements. We reviewed Statement of Financial Accounting Standards No. 13 (SFAS No. 13) and its related interpretations including Financial Accounting Standards Board Technical Bulletin 85-3 "Accounting for Operating Leases with Scheduled Rent Increases" (FTB 85-3), scheduled rent increases and rent holidays in an operating lease should be recognized by

11

the lessee on a straight-line basis over the lease term unless another systematic and rational allocation is more representative of the time pattern in which leased property is physically employed. FTB 85-3 specifically states that scheduled rent increases designed to reflect the anticipated effects of inflation is not a justification to support not straight lining the lease cost over the lease term. Based on our review, we have concluded that the straight-line method is required.

In accordance with the transition provisions of SAB No. 108, we recorded a \$3.4 million cumulative effect adjustment to retained earnings and an offsetting amount to long-term deferred rent as of January 1, 2007. In addition, we recognized an additional \$697,000 of facility rent expense for the six months ended June 30, 2007 related to the application of the straight-line methodology to certain leases with rent escalators.

Based on the nature of these adjustments and the totality of the circumstance surrounding these adjustments, we have concluded that these adjustments are immaterial to prior years' consolidated financial statements under our previous method of assessing materiality, and therefore, have elected, as permitted under the transition provisions of SAB No. 108, to reflect the effect of these adjustments in opening liabilities as of January 1, 2007, with the offsetting adjustment reflected as a cumulative effect adjustment to opening retained earnings as of January 1, 2007.

In July 2006, the FASB issued SFAS Interpretation No. 48, "Accounting for Uncertainty in Income Taxes - an interpretation of SFAS Statement No. 109" ("FIN 48"), and effective January 1, 2007, we adopted FIN 48. FIN 48 applies to all "tax positions" accounted for under SFAS 109. FIN 48 refers to "tax positions" as positions taken in a previously filed tax return or positions expected to be taken in a future tax return which are reflected in measuring current or deferred income tax assets and liabilities reported in the financial statements. FIN 48 further clarifies a tax position to include, but not be

Edgar Filing: RadNet, Inc. - Form 10-Q

limited to, the following:

- o an allocation or a shift of income between taxing jurisdictions,
- o the characterization of income or a decision to exclude reporting taxable income in a tax return, or
- o a decision to classify a transaction, entity, or other position in a tax return as tax exempt.

FIN 48 clarifies that a tax benefit may be reflected in the financial statements only if it is "more likely than not" that a company will be able to sustain the tax return position, based on its technical merits. If a tax benefit meets this criterion, it should be measured and recognized based on the largest amount of benefit that is cumulatively greater than 50% likely to be realized. This is a change from current practice, whereby companies may recognize a tax benefit only if it is probable a tax position will be sustained.

FIN 48 also requires that we make qualitative and quantitative disclosures, including a discussion of reasonably possible changes that might occur in unrecognized tax benefits over the next 12 months; a description of open tax years by major jurisdictions and a roll-forward of all unrecognized tax benefits, presented as a reconciliation of the beginning and ending balances of the unrecognized tax benefits on an aggregated basis.

We are subject to tax audits in several tax jurisdictions within the U.S. and will remain subject to examination until the statute of limitations expires for each respective tax jurisdiction. Tax audits by their very nature are often complex and can require several years to complete. Information relating to our tax examinations by jurisdiction is as follows:

- o Federal -- we are subject to U.S. federal tax examinations by tax authorities for the tax years ended 2003 to 2007
- o State -- we are subject to state tax examinations by tax authorities for the tax years ended 2002 to 2007

The adoption of FIN 48 did not have a material impact on our financial statements or disclosures. As of January 1, 2007 and September 30, 2007 we did not recognize any assets or liabilities for unrecognized tax benefits relative to uncertain tax positions. We do not currently anticipate that any significant increase or decrease to the gross unrecognized tax benefits will be recorded during the next 12 months. Any interest or penalties resulting from examinations will continue to be recognized as a component of the income tax provision; however, since there are no unrecognized tax benefits as a result of tax positions taken, there is no accrued interest and penalties.

Additionally, the future utilization of the Company's net operating loss carryforwards to offset future taxable income may be subject to a substantial annual limitation as a result of ownership changes that may have occurred previously or that could occur in the future.

12

NOTE 5 - COMPREHENSIVE LOSS

The following table summarizes total comprehensive loss for the applicable periods (in thousands):

Edgar Filing: RadNet, Inc. - Form 10-Q

| | Three Months Ended September 30, | | Nine Months Ended September 30, | |
|---|-------------------------------------|------------|------------------------------------|------------|
| | 2007 | 2006 | 2007 | 2006 |
| Net loss | \$ (1,955) | \$ (2,477) | \$ (5,369) | \$ (5,988) |
| Change in fair value of cash flow hedging | (2,864) | -- | (1,746) | -- |
| Total comprehensive loss | \$ (4,819) | \$ (2,477) | \$ (7,115) | \$ (5,988) |

NOTE 6 - EARNINGS PER SHARE

Earnings per share is based upon the weighted average number of shares of common stock and common stock equivalents outstanding, net of common stock held in treasury, and includes the effect of the one-for-two reverse stock split effective November 28, 2006, as follows (in thousands):

| | THREE MONTHS ENDED SEPTEMBER 30, | |
|---|-------------------------------------|------------|
| | 2007 | 2006 |
| Net loss | \$ (1,955) | \$ (2,477) |
| BASIC LOSS PER SHARE | | |
| Weighted average number of common shares outstanding during the period | 34,749 | 21,230 |
| Basic loss per share | \$ (0.06) | \$ (0.12) |
| DILUTED LOSS PER SHARE | | |
| Weighted average number of common shares outstanding during the period | 34,749 | 21,230 |
| Add additional shares issuable upon exercise of stock options and warrants calculated using the treasury stock method | -- | -- |
| Weighted average number of common shares used in calculating diluted earnings per share | 34,749 | 21,230 |
| Diluted loss per share | \$ (0.06) | \$ (0.12) |

For the three and nine months ended September 30, 2007 and 2006, we excluded all options and warrants in the calculation of diluted earnings per share because their effect is antidilutive.

NOTE 7 - INVESTMENT IN JOINT VENTURES

We have eight unconsolidated joint ventures with ownership interests ranging from 22% to 50%. These joint ventures represent partnerships with hospitals, health systems or radiology practices and were formed for the purpose of owning and operating diagnostic imaging centers. Professional services at the

Edgar Filing: RadNet, Inc. - Form 10-Q

joint venture diagnostic imaging centers are performed by contracted radiology practices or a radiology practice that participates in the joint venture. Our investment in these joint ventures is accounted for under the equity method. Total assets at September 30, 2007 include notes receivable from certain unconsolidated joint ventures aggregated \$376,000. Interest income related to these notes receivable was approximately \$14,000 and \$51,000 for the three and nine months ended September 30, 2007, respectively. We also received management service fees of \$1.4 million and \$3.6 million for the three and nine months ended September 30, 2007, respectively, in connection with operating the centers underlying these joint ventures.

The following table is a summary of key financial data for these joint ventures as of and for the nine months ended September 30, 2007 (in thousands):

13

| | |
|--------------------------------|----------|
| Balance Sheet Data: | |
| Current assets | \$15,531 |
| Noncurrent assets | 11,345 |
| Current liabilities | 2,018 |
| Noncurrent liabilities | 558 |
| Net assets: | |
| Radnet joint venture interests | 9,633 |
| Other joint venture partners | |
| interests | 14,667 |
| Income Statement Data: | |
| Net revenue | 44,080 |
| Net Income | 9,669 |

NOTE 8 - STOCK BASED COMPENSATION

We have three long-term incentive stock option plans. The 1992 plan has not issued options since the adoption of the 2000 plan and the 2000 plan has not issued options since the adoption of the 2006 plan. We reserved 1,000,000 shares of common stock for grants of options under our 2006 plan. We have issued non-qualified stock options from time to time in connection with acquisitions and for other purposes and have also issued stock under the plans. Employee stock options generally vest over three to five years and expire five to ten years from date of grant.

As of September 30, 2007, 202,750, or approximately 68%, of all outstanding stock options are fully vested. Options to acquire 95,000 shares of common stock were granted during the three and nine months ended September 30, 2007.

We have issued warrants under various types of arrangements to employees, as well as to non-employees in conjunction with debt financing and in exchange for outside services. All warrants are issued with an exercise price equal to the fair market value of the underlying common stock on the date of issuance. The warrants expire from five to seven years from the date of grant. Warrants issued to employees can vest immediately or up to seven years. Vesting terms are determined by the board of directors at the date of issuance. We issued no warrants during the three months ended September 30, 2007 and 1,450,000 warrants during the nine months ended September 30, 2007. As of September 30, 2007, warrants to acquire 3,753,667 shares, or approximately 73%, of all the outstanding warrants are fully vested.

As of November 1, 2005, we adopted SFAS No. 123(R), "Share-Based Payment," applying the modified prospective method. This Statement requires all equity-based payments to employees, including grants of employee options, to be

Edgar Filing: RadNet, Inc. - Form 10-Q

recognized in the consolidated statement of earnings based on the grant date fair value of the award. Under the modified prospective method, we are required to record equity-based compensation expense for all awards granted after the date of adoption and for the unvested portion of previously granted awards outstanding as of the date of adoption. The fair values of all options were valued using a Black-Scholes model.

In anticipation of the adoption of SFAS No. 123(R), we did not modify the terms of any previously granted awards.

Mssrs. Linden, Hames and Stolper who hold the positions of Executive Vice President and General Counsel, Executive Vice President and Chief Operating Officer, Western Operations and Executive Vice President and Chief Financial Officer, respectively, were issued certain warrants in prior periods which fully vest upon the sooner of their respective multi-year vesting schedules or at such time as the 30 day average closing stock price of our shares in the public market in which it trades equals or exceeds \$6.00. For the 30 day trading period ended March 7, 2007, the average closing price exceeded \$6.00 per share. Accordingly, these warrants fully vested resulting in the full expensing of the remaining unamortized fair value of these warrants of \$1.7 million in the first quarter of 2007.

The compensation expense recognized for all equity-based awards is net of estimated forfeitures and is recognized over the awards' service period. In accordance with Staff Accounting Bulletin ("SAB") No. 107, we classified equity-based compensation in operating expenses with the same line item as the majority of the cash compensation paid to employees.

The following tables illustrate the impact of equity-based compensation on reported amounts (in thousands):

14

| | THREE MONTHS ENDED SEPTEMBER 30, 2007 | | |
|--------------------------------------|--|------------------------------|--------------------------|
| | ---- | | |
| | IMPACT OF AS REPORTED | EQUITY-BASED COMPENSATION | IMPACT OF AS REPORTED |
| | ----- | ----- | ----- |
| Income from operations | \$ 8,880 | \$ (281) | \$ 3,582 |
| Net loss | (1,955) | (281) | (2,477) |
| Net basic and diluted loss per share | (0.06) | (0.01) | (0.12) |

| | NINE MONTHS ENDED SEPTEMBER 30, 2007 | | |
|--------------------------------------|---|------------------------------|--------------------------|
| | ---- | | |
| | IMPACT OF AS REPORTED | EQUITY-BASED COMPENSATION | IMPACT OF AS REPORTED |
| | ----- | ----- | ----- |
| Income from operations | \$ 24,526 | \$ (2,883) | \$ 12,314 |
| Net loss | (5,369) | (2,883) | (5,988) |
| Net basic and diluted loss per share | (0.16) | (0.08) | (0.29) |

Edgar Filing: RadNet, Inc. - Form 10-Q

The following summarizes all of our option and warrant activity for the nine months ended September 30, 2007:

| OUTSTANDING OPTIONS | SHARES | WEIGHTED AVERAGE EXERCISE PRICE PER COMMON SHARE | WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (IN YEARS) |
|-----------------------------------|-----------|--|---|
| ----- | ----- | ----- | ----- |
| Balance, December 31, 2006 | 350,625 | \$1.01 | |
| Granted | 95,000 | 9.50 | |
| Exercised | (138,125) | 0.85 | |
| Canceled or expired | (7,250) | 3.26 | |
| Balance, September 30, 2007 | 300,250 | \$3.72 | 5.11 |
| | ----- | | |
| Exercisable at September 30, 2007 | 202,750 | \$1.02 | 1.93 |
| | ----- | | |

| OUTSTANDING WARRANTS | SHARES | WEIGHTED AVERAGE EXERCISE PRICE PER COMMON SHARE | WEIGHTED AVERAGE REMAINING CONTRACTUAL LIFE (IN YEARS) |
|-----------------------------------|-----------|--|---|
| ----- | ----- | ----- | ----- |
| Balance, December 31, 2006 | 4,590,667 | \$1.20 | |
| Granted | 1,450,000 | 5.32 | |
| Exercised | (612,000) | 0.93 | |
| Canceled or expired | (282,000) | 2.47 | |
| Balance, September 30, 2007 | 5,146,667 | \$2.32 | 3.48 |
| | ----- | | |
| Exercisable at September 30, 2007 | 3,753,667 | \$3.61 | 1.16 |
| | ----- | | |

The aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between our closing stock price on September 30, 2007 and the exercise price, multiplied by the number of in-the-money options/warrants) that would have been received by the holder had all holders exercised their options/warrants on September 30, 2007. Total intrinsic value of options and warrants exercised during the nine months ended September 30, 2007 was approximately \$6.1 million. As of September 30, 2007, total unrecognized share-based compensation expense related to non-vested employee awards was approximately \$4.9 million, which is expected to be recognized over a weighted average period of approximately 4.4 years.

The fair value of each option/warrant granted is estimated on the grant date using the Black-Scholes option pricing model which takes into account as of the grant date the exercise price and expected life of the option/warrant, the current price of the underlying stock and its expected volatility, expected

Edgar Filing: RadNet, Inc. - Form 10-Q

dividends on the stock and the risk-free interest rate for the term of the option/warrant. The weighted-average grant date fair value of stock options and warrants granted during the nine months ended September 30, 2007 was \$3.80 and was \$0.47 for the nine months ended September 30, 2006. The following is the weighted average data used to calculate the fair value:

| | Risk-free Interest Rate | Expected Life | Expected Volatility | Expected Dividends |
|--------------------|----------------------------|------------------|------------------------|-----------------------|
| | ----- | ---- | ----- | ----- |
| September 30, 2007 | 4.64% | 4.1 years | 94.65% | --- |
| September 30, 2006 | 4.73% | 4.72 years | 99.36% | --- |

We have determined the expected term assumption under the "Simplified Method" as defined in SAB 107. The expected stock price volatility is based on the historical volatility of our stock. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant with an equivalent remaining term. We have not paid dividends in the past and do not currently plan to pay any dividends in the near future.

NOTE 9 - SUBSEQUENT EVENTS

On October 9, 2007, we completed our purchase of Liberty Pacific Imaging located in Encino, California for \$2.8 million. The center operates a successful MRI practice utilizing a 3T MRI unit, the strongest magnet strength commercially available at this time. The center was founded in 2003, and has since been a fixture in the Encino/Tarzana market of the San Fernando Valley in Los Angeles. The acquisition allows us to consolidate a portion of our Encino/Tarzana MRI volume onto the existing Liberty Pacific scanner. This consolidation will make available our existing 3T MRI unit in that market, which will be moved to our Squadron facility in Rockland County, New York.

On October 15 2007 we divested a non-course center in Golden, Colorado for \$325,000.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

OVERVIEW

Since our acquisition of Radiologix on November 15, 2006, we have operated a group of regional networks comprised of 143 diagnostic imaging facilities located in seven states with operations primarily in California, the Mid-Atlantic, the Treasure Coast area of Florida, Kansas and the Finger Lakes (Rochester) and Hudson Valley areas of New York, providing diagnostic imaging services including MRI, CT, PET, nuclear medicine, mammography, ultrasound, X-ray, and fluoroscopy. The Company's operations comprise a single segment for financial reporting purposes.

The results of operations of Radiologix and its wholly-owned subsidiaries have been included in the consolidated financial statements from the date of acquisition. The consolidated financial statements also include the accounts of RadNet, Inc., Radnet Management, Inc., or Radnet Management, and BRMG, which is a professional partnership, all collectively referred to as "us" or "we". The consolidated financial statements also include Radnet Sub, Inc., Radnet Management I, Inc., Radnet Management II, Inc., SoCal MR Site Management, Inc., and Diagnostic Imaging Services, Inc., or DIS, all wholly owned subsidiaries of Radnet Management.

Howard G. Berger, M.D. is our President and Chief Executive Officer, a member of our Board of Directors and owns approximately 17% of our outstanding

Edgar Filing: RadNet, Inc. - Form 10-Q

common stock. Dr. Berger also owns, indirectly, 99% of the equity interests in BRMG. BRMG provides all of the professional medical services at 52 of our facilities located in California under a management agreement with us, and contracts with various other independent physicians and physician groups to provide the professional medical services at most of our other California facilities. We obtain professional medical services from BRMG in California, rather than provide such services directly or through subsidiaries, in order to comply with California's prohibition against the corporate practice of medicine. However, as a result of our close relationship with Dr. Berger and BRMG, we believe that we are able to better ensure that medical service is provided at our California facilities in a manner consistent with our needs and expectations and those of our referring physicians, patients and payors than if we obtained these services from unaffiliated physician groups. At eleven former Radiologix centers

16

in California and at all of the former Radiologix centers which are located outside of California, we have entered into long-term contracts with prominent radiology groups in the area to provide physician services at those facilities. The operations of BRMG are consolidated with us as a result of the contractual and operational relationship among BRMG, Dr. Berger, and us. We are considered to have a controlling financial interest in BRMG pursuant to the guidance in Emerging Issues Task Force Issue 97-2 (EITF 97-2). BRMG is a partnership of Pronet Imaging Medical Group, Inc. and Beverly Radiology Medical Group, both of which are 99%-owned by Dr. Berger. RadNet provides non-medical, technical and administrative services to BRMG for which it receives a management fee.

Radiologix, our wholly-owned subsidiary, contracts with radiology practices to provide professional services, including supervision and interpretation of diagnostic imaging procedures' performed in its diagnostic imaging centers. The radiology practices maintain full control over the provision of professional radiological services. The contracted radiology practices generally have outstanding physician and practice credentials and reputations; strong competitive market positions; a broad sub-specialty mix of physicians; a history of growth and potential for continued growth.

Radiologix enters into long-term agreements with radiology practice groups (typically 40 years). Under these arrangements, in addition to obtaining technical fees for the use of our diagnostic imaging equipment and the provision of technical services, it provides management services and receives a fee based on the practice group's professional revenue, including revenue derived outside of its diagnostic imaging centers. Radiologix owns the diagnostic imaging assets and, therefore, receives 100% of the technical reimbursements associated with imaging procedures.

Radiologix has no financial controlling interest in the contracted radiology practices, as defined in EITF 97-2; accordingly, we do not consolidate the financial statements of those practices in our consolidated financial statements.

All of our facilities employ state-of-the-art equipment and technology in modern, patient-friendly settings. Many of our facilities within a particular region are interconnected and integrated through our advanced information technology system. One hundred-four of our facilities are multi-modality sites, offering various combinations of magnetic resonance imaging, or MRI, computed tomography, or CT, positron emission tomography, or PET, nuclear medicine, mammography, ultrasound, diagnostic radiology, or X-ray and fluoroscopy. Thirty-nine of our facilities are single-modality sites, offering either X-ray or MRI. Consistent with our regional network strategy, we locate our

Edgar Filing: RadNet, Inc. - Form 10-Q

single-modality facilities near multi-modality sites to help accommodate overflow in targeted demographic areas.

At our facilities, we provide all of the equipment as well as all non-medical operational, management, financial and administrative services necessary to provide diagnostic imaging services. We give our facility managers authority to run our facilities to meet the demands of local market conditions, while our corporate structure provides economies of scale, corporate training programs, standardized policies and procedures and sharing of best practices across our networks. Each of our facility managers is responsible for meeting our standards of patient service, managing relationships with local physicians and payors and maintaining profitability.

We derive substantially all of our revenue, directly or indirectly, from fees charged for the diagnostic imaging services performed at our facilities.

ADOPTION OF THE PROVISIONS OF STAFF ACCOUNTING BULLETIN NO. 108 ("SAB NO. 108")

In September 2006, the SEC issued Staff Accounting Bulletin No. 108 ("SAB No. 108"), "Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements." SAB No. 108 specifies how the carryover or reversal of prior year unrecorded financial statement misstatements should be considered in quantifying a current year misstatement. SAB No. 108 requires an approach that considers the amount by which the current year Consolidated Statement of Operations is misstated ("rollover approach") and an approach that considers the cumulative amount by which the current year Consolidated Balance Sheet is misstated ("iron curtain approach").

Prior to the issuance of SAB No. 108, either the rollover or iron curtain approach was acceptable for assessing the materiality of financial statement misstatements. Prior to the Company's application of the guidance in SAB No. 108, management used the rollover approach for quantifying financial statement misstatements.

Initial application of SAB No. 108 allows registrants to elect not to restate prior periods but to reflect the initial application in their annual financial statements covering the first fiscal year ending after November 15, 2006. The cumulative effect of the initial application should be reported in the carrying amounts of assets and liabilities as of the beginning of that fiscal year and the offsetting adjustment, net of tax, should be made to the opening balance of retained earnings for that year. We elected to record the effects of applying SAB No. 108 using the cumulative effect transition method. The misstatement that has been corrected is described below.

17

Subsequent to the completion of the financial statement close process for the three and six months ended June 30, 2007, we determined that certain lease rate escalation clauses had not been properly accounted for in accordance with generally accepted accounting principles for the fiscal years ended October 31, 2004, 2005 and 2006 as well as for the two months ended December 31, 2006 (our transition period) and for the quarter ended March 31, 2007. The Company had been recording rent expense based on the contractual terms of the lease agreements. We reviewed Statement of Financial Accounting Standards No. 13 (SFAS No. 13) and its related interpretations including Financial Accounting Standards Board Technical Bulletin 85-3 "Accounting for Operating Leases with Scheduled Rent Increases" (FTB 85-3), scheduled rent increases and rent holidays in an operating lease should be recognized by the lessee on a straight-line basis over the lease term unless another systematic and rational allocation is more

Edgar Filing: RadNet, Inc. - Form 10-Q

representative of the time pattern in which leased property is physically employed. FTB 85-3 specifically states that scheduled rent increases designed to reflect the anticipated effects of inflation is not a justification to support not straight lining the lease cost over the lease term. Based on our review, we have concluded that the straight-line method is required.

In accordance with the transition provisions of SAB No. 108, we recorded a \$3.4 million cumulative effect adjustment to retained earnings and an offsetting amount to long-term deferred rent as of January 1, 2007. In addition, we recognized an additional \$697,000 of facility rent expense for the six months ended June 30, 2007 related to the application of the straight-line methodology to certain leases with rent escalators.

Based on the nature of these adjustments and the totality of the circumstance surrounding these adjustments, we have concluded that these adjustments are immaterial to prior years' consolidated financial statements under our previous method of assessing materiality, and therefore, have elected, as permitted under the transition provisions of SAB No. 108, to reflect the effect of these adjustments in opening liabilities as of January 1, 2007, with the offsetting adjustment reflected as a cumulative effect adjustment to opening retained earnings as of January 1, 2007.

CRITICAL ACCOUNTING ESTIMATES

Our discussion and analysis of financial condition and results of operations are based on our consolidated financial statements that were prepared in accordance with U.S. generally accepted accounting principles, or GAAP. Management makes estimates and assumptions when preparing financial statements. These estimates and assumptions affect various matters, including:

- o Our reported amounts of assets and liabilities in our consolidated balance sheets at the dates of the financial statements;
- o Our disclosure of contingent assets and liabilities at the dates of the financial statements; and
- o Our reported amounts of net revenue and expenses in our consolidated statements of operations during the reporting periods.

These estimates involve judgments with respect to numerous factors that are difficult to predict and are beyond management's control. As a result, actual amounts could materially differ from these estimates.

The Securities and Exchange Commission (SEC), defines critical accounting estimates as those that are both most important to reflect a company's financial condition and results of operations and require management's most difficult, subjective or complex judgment, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and may change in subsequent periods.

As of the period covered in this report, there have been no material changes to the critical accounting estimates we use, and have explained, in both our annual report on Form 10-K for the fiscal year ended October 31, 2006 and our transition report on Form 10-K/T for the two months ended December 31, 2006.

RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, the percentage

Edgar Filing: RadNet, Inc. - Form 10-Q

that certain items in the statement of operations bears to net revenue.

| | THREE MONTHS ENDED SEPTEMBER 30, | | NIN S |
|--|-------------------------------------|--------|----------|
| | 2007 | 2006 | 200 |
| NET REVENUE | 100.0% | 100.0% | 100 |
| OPERATING EXPENSES | | | |
| Operating expenses | 75.8% | 75.7% | 75 |
| Depreciation and amortization | 10.3% | 10.3% | 10 |
| Provision for bad debts | 5.8% | 4.2% | 6 |
| Loss on sale of equipment | 0.0% | 0.8% | 0 |
| Severance costs | 0.0% | 0.0% | 0 |
| Total operating expenses | 91.9% | 91.1% | 92 |
| INCOME FROM OPERATIONS | 8.1% | 8.9% | 7 |
| OTHER EXPENSES (INCOME) | | | |
| Interest expense | 10.6% | 15.3% | 10 |
| Loss on debt extinguishment, net | 0.0% | -0.1% | 0 |
| Other expense (income) | 0.0% | 0.1% | 0 |
| Total other expense | 10.6% | 15.3% | 10 |
| LOSS BEFORE INCOME TAXES, MINORITY | | | |
| INTERESTS AND EARNINGS FROM | | | |
| JOINT VENTURES | -2.5% | -6.4% | -2 |
| Provision for income taxes | -0.1% | 0.0% | 0 |
| Minority interest in (income) loss of subs | -0.2% | 0.0% | -0 |
| Earnings from joint ventures | 1.0% | 0.2% | 1 |
| NET LOSS | -1.8% | -6.2% | -1 |

THREE MONTHS ENDED SEPTEMBER 30, 2007 COMPARED TO THE THREE MONTHS ENDED
SEPTEMBER 30, 2006

NET REVENUE

Net revenue for the three months ended September 30, 2007 was \$110.2 million compared to \$40.0 million for the three months ended September 30, 2006, an increase of \$70.2 million, or 175.3%. Net revenue from the acquisition of Radiologix, effective November 15, 2006, was \$67.6 million for the three months ended September 30, 2007. Net revenue excluding Radiologix increased \$2.6 million for the three months ended September 30, 2007 when compared to the same period last year. This increase is mainly due to an increase in procedure volumes from existing centers as well as from the addition of new centers and is net of the effects of reimbursement reductions experienced as a result of the government's reduction of certain Medicare payments (DRA), which became effective in January 2007.

OPERATING EXPENSES

Edgar Filing: RadNet, Inc. - Form 10-Q

Operating expenses for the three months ended September 30, 2007 increased approximately \$53.2 million, or 175.4%, from \$30.3 million for the three months ended September 30, 2006 to \$83.5 million for the three months ended September 30, 2007. The following table sets forth our operating expenses for the three months ended September 30, 2007 and 2006 (in thousands):

19

Salaries and professional reading fees (excluding stock based compensation and severance)
Stock based compensation
Building and equipment rental
General administrative expenses

Total operating expenses

Depreciation and amortization
Provision for bad debts
Loss on sale of equipment, net
Severance costs

SALARIES AND PROFESSIONAL READING FEES (EXCLUDING STOCK COMPENSATION AND SEVERANCE)

Salaries and professional reading fees increased \$25.9 million, or 135.4%, to \$45.1 million for the three months ended September 30, 2007 compared to \$19.2 million for the three months ended September 30, 2006. During the three months ended September 30, 2007, salaries and professional reading fees were \$23.3 million for Radiologix. Salaries excluding Radiologix increased \$2.6 million for the three months ended September 30, 2007 when compared to the same period last year.

STOCK BASED COMPENSATION

Stock compensation increased \$165,000 to \$281,000 for the three months ended September 30, 2007 compared to \$116,000 for the three months ended September 30, 2006. This increase is primarily due to additional options and warrants granted during the last three months of 2006 and the first nine months of 2007.

SEVERANCE

During the three months ended September 30, 2007, we recorded severance costs of \$30,000 associated with the integration of Radiologix.

BUILDING AND EQUIPMENT RENTAL

Edgar Filing: RadNet, Inc. - Form 10-Q

Building and equipment rental expenses increased \$8.7 million, or 386.3%, to \$10.9 million for the three months ended September 30, 2007 compared to \$2.2 million for the three months ended September 30, 2006. During the three months ended September 30, 2007, building and equipment rental expense was \$7.9 million for Radiologix. Building and equipment rental expenses excluding Radiologix increased \$800,000 for the three months ended September 30, 2007 when compared to the same period last year. The increase was due to normal consumer price index escalations built into existing operating leases as well as additional facility rent from new centers, including approximately \$240,000 from centers acquired during 2007 (see Note 3 to our consolidated financial statements).

GENERAL AND ADMINISTRATIVE EXPENSES

General and administrative expenses include billing fees, medical supplies, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses. Many of these expenses are variable in nature including medical supplies and billing fees, which increase with volume and repairs and maintenance under our GE service agreement at 3.62% of net revenue for the three-month period. Overall, general and administrative expenses increased \$18.4 million, or 208.9%, for the three months ended September 30, 2007 compared to the previous period. During the three months ended September 30, 2007, general and administrative expenses were \$15.5 million for Radiologix. General and administrative expenses excluding Radiologix increased \$2.9 million for the three months ended September 30, 2007 when compared to the same period last year. The increase is in line with our increase in procedure volumes at both existing centers as well as new centers. Also in this increase are increased expenditures for accounting fees associated with our efforts towards compliance with the Sarbanes-Oxley Act of 2002 by our deadline of December 2007.

20

DEPRECIATION AND AMORTIZATION

Depreciation and amortization increased \$7.3 million, or 176.1%, to \$11.4 million for the three months ended September 30, 2007 when compared to the same period last year. During the three months ended September 30, 2007, depreciation and amortization expense was \$6.5 million for Radiologix, which includes \$1.1 million of amortization of intangible assets associated with the fair value of management service agreements and covenants not to compete. Depreciation and amortization expense excluding Radiologix increased \$800,000 for the three months ended September 30, 2007 when compared to the same period last year. The increase is primarily due to property and equipment additions as well as the acceleration of the amortization of leasehold improvements related to our vacated San Gabriel facility of approximately \$184,000.

PROVISION FOR BAD DEBT

Provision for bad debts increased \$4.7 million, or 276.8%, to \$6.4 million, or 5.8% of net revenue, for the three months ended September 30, 2007 compared to \$1.7 million, or 4.2% of net revenue, for the three months ended September 30, 2006. During the three months ended September 30, 2007, the provision for bad debt was \$5.1 million, or 7.6% of net revenue, for Radiologix. Historically, Radiologix has

Edgar Filing: RadNet, Inc. - Form 10-Q

experienced higher bad debt expense as compared to our business pre-acquisition due to the higher concentration of business associated with hospital payers in the markets that Radiologix serves and the poor collection percentages that are inherent with hospital business. Provision for bad debts excluding Radiologix decreased \$400,000 for the three months ended September 30, 2007 when compared to the same period last year.

INTEREST EXPENSE

Interest expense for the three months ended September 30, 2007 increased approximately \$5.5 million, or 90.3%, from the same period in 2006. The increase was primarily due to the increased indebtedness of \$360 million incurred upon the acquisition of Radiologix as well as an addition to our first lien Term Loan B of \$25 million in August 2007. Also included is the amortization of our deferred finance costs associated with this new financing which was approximately \$498,000 for the three months ended September 30, 2007 as well as realized losses on our fair value hedges of \$712,000 for the three months ended September 30, 2007.

MINORITY INTEREST IN INCOME OF SUBSIDIARIES

For the three months ended September 30, 2007, we recognized \$198,000 in minority interest expense related to consolidated joint ventures of Radiologix.

EQUITY IN EARNINGS FROM UNCONSOLIDATED JOINT VENTURES

For the three months ended September 30, 2007, we recognized equity in earnings from unconsolidated joint ventures of \$1,103,000, including \$1,079,000 from investments of Radiologix and \$24,000 from an investment in a PET center in Palm Desert, California.

NINE MONTHS ENDED SEPTEMBER 30, 2007 COMPARED TO THE NINE MONTHS ENDED SEPTEMBER 30, 2006

NET REVENUE

Net revenue for the nine months ended September 30, 2007 was \$323.1 million compared to \$120.0 million for the nine months ended September 30, 2006, an increase of \$203.0 million, or 169.1%. Net revenue from the acquisition of Radiologix, effective November 15, 2006, was \$197.6 million for the nine months ended September 30, 2007. Net revenue excluding Radiologix increased \$5.4 million for the nine months ended September 30, 2007 when compared to the same period last year. This increase is mainly due to an increase in procedure volumes from existing centers as well as from the addition of new centers and is net of the effects of reimbursement reductions experienced as a result of the government's reduction of certain Medicare payments (DRA), which became effective in January 2007.

OPERATING EXPENSES

Operating expenses for the nine months ended September 30, 2007 increased approximately \$154.3 million, or 171.1%, from \$90.1 million for the nine months ended September 30, 2006 to \$244.4 million for the

Edgar Filing: RadNet, Inc. - Form 10-Q

nine months ended September 30, 2007. The following table sets forth our operating expenses for the nine months ended September 30, 2007 and 2006 (in thousands):

Salaries and professional reading fees (excluding stock based compensation and severance)
Stock based compensation
Building and equipment rental
General administrative expenses
NASDAQ one-time listing fee

Total operating expenses

Depreciation and amortization
Provision for bad debts
Loss on sale of equipment, net
Severance costs

SALARIES AND PROFESSIONAL READING FEES (EXCLUDING STOCK COMPENSATION AND SEVERANCE)

Salaries and professional reading fees increased \$74.1 million, or 131.3%, to \$130.6 million for the nine months ended September 30, 2007 compared to \$56.5 million for the nine months ended September 30, 2006. During the nine months ended September 30, 2007, salaries and professional reading fees were \$67.0 million for Radiologix. Salaries excluding Radiologix increased \$7.1 million for the nine months ended September 30, 2007 when compared to the same period last year, which is in line with DRA effected increases in net revenue and increases in our procedure volumes.

STOCK BASED COMPENSATION

Stock compensation increased \$2.5 million to \$2.9 million for the nine months ended September 30, 2007 compared to \$392,000 for the nine months ended September 30, 2006. This increase is primarily due to additional options and warrants granted during the last three months of 2006 and the first nine months of 2007. Also included in this increase is \$1.7 million of additional stock based compensation expense recorded during the nine months ended September 30, 2007 as a result of the vesting of warrants.

Messrs. Linden, Hames and Stolper who hold the positions of Executive Vice President and General Counsel, Executive Vice President and Chief Operating Officer, Western Operations and Executive Vice President and Chief Financial Officer, respectively, were issued certain warrants in prior periods which fully vest upon the sooner of their respective multi-year vesting schedules or at such time as the 30 day average closing stock price of our shares in the public market in which it trades equals or exceeds \$6.00. For the 30 day trading period ended March 7, 2007, the average closing price exceeded \$6.00 per share. Accordingly, these warrants fully vested resulting in the full

Edgar Filing: RadNet, Inc. - Form 10-Q

expensing of the remaining unamortized fair value of these warrants of \$1.7 million.

SEVERANCE

During the nine months ended September 30, 2007, we recorded severance costs of \$815,000 associated with the integration of Radiologix.

BUILDING AND EQUIPMENT RENTAL

Building and equipment rental expenses increased \$24.6 million, or 378.6%, to \$31.0 million for the nine months ended September 30, 2007 compared to \$6.5 million for the nine months ended September 30, 2006. During the nine months ended September 30, 2007, building and equipment rental expense was \$22.4 million for Radiologix. Building and equipment rental expenses excluding Radiologix increased \$2.2 million for the nine months ended September 30, 2007

22

when compared to the same period in the previous year. The increase was due to normal consumer price index escalations built into existing operating leases as well as additional facility rent from new centers including approximately \$288,000 from centers acquired during 2007 (see Note 3 to our consolidated financial statements). Also included in this increase is \$638,000 resulting from straight-lining the built-in rent escalators existing in some of our lease contracts.

GENERAL AND ADMINISTRATIVE EXPENSES

General and administrative expenses include billing fees, medical supplies, office supplies, repairs and maintenance, insurance, business tax and license, outside services, utilities, marketing, travel and other expenses. Many of these expenses are variable in nature, including medical supplies and billing fees, which increase with volume and repairs, and maintenance under our GE service agreement at 3.62% of net revenue for the nine-month period. Overall, general and administrative expenses increased \$53.0 million, or 197.6%, for the nine months ended September 30, 2007 compared to the previous period. During the nine months ended September 30, 2007, general and administrative expenses were \$46.5 million for Radiologix. General and administrative expenses excluding Radiologix increased \$6.5 million for the nine months ended September 30, 2006 when compared to the same period last year. The increase is in line with our increase in procedure volumes at both existing centers as well as new centers. Also in this increase are increased expenditures for accounting fees associated with our efforts towards compliance with the Sarbanes-Oxley Act of 2002 by our deadline of December 2007.

NASDAQ ONE-TIME LISTING FEE

During the nine months ended September 30, 2007, we recorded \$120,000 for fees associated with listing our common stock with NASDAQ.

DEPRECIATION AND AMORTIZATION

Depreciation and amortization increased \$20.3 million, or 166.7%, to \$32.5 million for the nine months ended September 30, 2007 when compared to the same period last year. During the nine months ended

Edgar Filing: RadNet, Inc. - Form 10-Q

September 30, 2007, depreciation and amortization expense was \$18.1 million for Radiologix, which includes \$3.2 million of amortization of intangible assets associated with the fair value of management service agreements and covenants not to compete. Depreciation and amortization expense excluding Radiologix increased \$2.2 million for the nine months ended September 30, 2007 when compared to the same period last year primarily due to property and equipment additions, as well as the acceleration of the amortization of leasehold improvements related to our vacated Orange, Rancho Bernardo and San Gabriel facilities of approximately \$716,000.

PROVISION FOR BAD DEBT

Provision for bad debt increased \$15.8 million, or 314.4%, to \$20.8 million, or 6.4% of net revenue, for the nine months ended September 30, 2007 compared to \$5.0 million, or 4.2% of net revenue, for the nine months ended September 30, 2006. During the nine months ended September 30, 2007, the provision for bad debt was \$15.8 million, or 8.0% of net revenue, for Radiologix. Historically, Radiologix has experienced higher bad debt as compared to our business pre-acquisition due to the higher concentration of business associated with hospital payers in the markets that Radiologix serves and the poor collection percentages that are inherent with hospital business. Provision for bad debts excluding Radiologix was unchanged at \$5.0 million for the nine months ended September 30, 2007 and 2006.

INTEREST EXPENSE

Interest expense for the nine months ended September 30, 2007 increased approximately \$16.9 million, or 109.1%, from the same period in 2006. The increase was primarily due to the increased indebtedness of \$360 million incurred upon the acquisition of Radiologix as well as an addition to our first lien Term Loan B of \$25 million in August 2007. Also included is the amortization of our deferred finance costs associated with this new financing which was approximately \$1.5 million for the nine months ended September 30, 2007 as well as realized losses on our fair value hedges of \$155,000 for the nine months ended September 30, 2007.

23

MINORITY INTEREST IN INCOME OF SUBSIDIARIES

For the nine months ended September 30, 2007, we recognized \$483,000 in minority interest expense related to consolidated joint ventures of Radiologix.

EQUITY IN EARNINGS FROM UNCONSOLIDATED JOINT VENTURES

For the nine months ended September 30, 2007, we recognized equity in earnings from unconsolidated joint ventures of \$3,080,000 including \$3,008,000 from investments of Radiologix and \$72,000 from an investment in a PET center in Palm Desert, California.

LIQUIDITY AND CAPITAL RESOURCES

On November 15, 2006, we entered into a \$405 million senior secured credit facility with GE Commercial Finance Healthcare Financial Services (the "November 2006 Credit Facility"). This facility was used to finance our acquisition of Radiologix, refinance existing indebtedness, pay transaction costs and expenses relating to our acquisition of Radiologix, and to provide financing for working capital needs post-acquisition. The facility consists of a revolving credit facility of up to \$45 million, a \$225 million first lien Term

Edgar Filing: RadNet, Inc. - Form 10-Q

Loan and a \$135 million second lien Term Loan. The revolving credit facility has a term of five years, the term loan has a term of six years and the second lien term loan has a term of six and one-half years. Interest is payable on all loans initially at an Index Rate plus the Applicable Index Margin, as defined. The Index Rate is initially a floating rate equal to the higher of the rate quoted from time to time by The Wall Street Journal as the "base rate on corporate loans posted by at least 75% of the nation's largest 30 banks" or the Federal Funds Rate plus 50 basis points. The Applicable Index Margin on each of the revolving credit facility and the term loan is 2% and on the second lien term loan is 6%. We may request that the interest rate instead be based on LIBOR plus the Applicable LIBOR Margin, which is 3.5% for the revolving credit facility and the term loan and 7.5% for the second lien term loan. The credit facility includes customary covenants for a facility of this type, including minimum fixed charge coverage ratio, maximum total leverage ratio, maximum senior leverage ratio, limitations on indebtedness, contingent obligations, liens, capital expenditures, lease obligations, mergers and acquisitions, asset sales, dividends and distributions, redemption or repurchase of equity interests, subordinated debt payments and modifications, loans and investments, transactions with affiliates, changes of control, and payment of consulting and management fees.

On August 23, 2007 we secured an incremental \$35 million ("Incremental Facility") as part of our existing credit facilities with GE Commercial Finance Healthcare Financial Services. The Incremental Facility consists of an additional \$25 million as part of our first lien Term Loan B and \$10 million of additional capacity under our existing revolving line of credit. The Incremental Facility will be used to fund certain identified strategic initiatives and for general corporate purposes. The terms of our first lien term loan as explained above will remain unchanged.

As part of the financing, we swapped 50% of the aggregate principal amount of the facilities to a floating rate within 90 days of the closing. On April 11, 2006, effective April 28, 2006, we entered into an interest rate swap on \$73.0 million fixing the LIBOR rate of interest at 5.47% for a period of three years. This swap was made in conjunction with the \$161.0 million credit facility that closed on March 9, 2006. In addition, on November 15, 2006, we entered into an interest rate swap on \$107.0 million fixing the LIBOR rate of interest at 5.02% for a period of three years, and on November 28, 2006, we entered into an interest rate swap on \$90.0 million fixing the LIBOR rate of interest at 5.03% for a period of three years. Previously, the interest rate on the above \$270.0 million portion of the credit facility was based upon a spread over LIBOR which floats with market conditions.

The Company documents its risk management strategy and hedge effectiveness at the inception of the hedge, and, unless the instrument qualifies for the short-cut method of hedge accounting, over the term of each hedging relationship. The Company's use of derivative financial instruments is limited to interest rate swaps, the purpose of which is to hedge the cash flows of variable-rate indebtedness. The Company does not hold or issue derivative financial instruments for speculative purposes. In accordance with Statement of Financial Accounting Standards No. 133, derivatives that have been designated and qualify as cash flow hedging instruments are reported at fair value. The gain or loss on the effective portion of the hedge (i.e., change in fair value) is initially reported as a component of other comprehensive income in the Company's Consolidated Statement of Stockholders' Equity. The remaining gain or loss, if any, is recognized currently in earnings. Of the derivatives that were not designated as cash flow hedging instruments, we recorded an increase to interest expense of approximately \$289,000 for the nine months ended September 30, 2007. The corresponding liability of \$442,000 is included in the other non-current liabilities in the consolidated balance sheet at September 30, 2007. This liability was \$710,000 at December 31, 2006.

We operate in a capital intensive, high fixed-cost industry that requires significant amounts of capital to fund operations. In addition to operations, we require significant amounts of capital for the initial start-up and development expense of new diagnostic imaging facilities, the acquisition of additional facilities and new diagnostic imaging equipment, and to service our existing debt and contractual obligations. Because our cash flows from operations have been insufficient to fund all of these capital requirements, we have depended on the availability of financing under credit arrangements with third parties.

Our business strategy with regard to operations will focus on the following:

- |X| Maximizing performance at our existing facilities;
- |X| Focusing on profitable contracting;
- |X| Expanding MRI, CT and PET applications;
- |X| Optimizing operating efficiencies; and
- |X| Expanding our networks

Our ability to generate sufficient cash flow from operations to make payments on our debt and other contractual obligations will depend on our future financial performance. A range of economic, competitive, regulatory, legislative and business factors, many of which are outside of our control, will affect our financial performance. Taking these factors into account, including our historical experience and our discussions with our lenders to date, although no assurance can be given, we believe that through implementing our strategic plans and continuing to restructure our financial obligations, we will obtain sufficient cash to satisfy our obligations as they become due in the next twelve months.

SOURCES AND USES OF CASH

Cash decreased during the nine months ended September 30, 2007 to zero from \$3.2 million at December 31, 2006.

Cash provided by operating activities for the nine months ended September 30, 2007 was \$20.7 million compared to \$7.8 million for the same period in 2006.

Cash used by investing activities for the nine months ended September 30, 2007 was \$34.3 million compared to cash used of \$10.9 million for the same period in 2006. For the nine months ended September 30, 2007 and 2006, we purchased property and equipment for approximately \$19.4 million and \$7.5 million, respectively. During the nine months ended September 30, 2007, we recorded the purchase of imaging facilities of \$15.7 million (see Note 3 to our consolidated financial statements) compared to \$3.4 million during the nine months ended September 30, 2006. Also, during the nine months ended September 30, 2007, we generated \$1.3 million of cash from the sale of one of our imaging facilities acquired through our purchase of Radiologix.

Cash generated from financing activities for the nine months ended September 30, 2007 was \$10.4 million compared to \$3.1 million for the same period in 2006. The primary source of cash during the nine months ended September 30, 2007 is our addition to our first lien term loan B with GE of \$25 million. This was offset by the classification of \$6.9 million as restricted under the terms of our addition to our first lien term loan B. Also included in our cash generated from financing was \$549,000 of cash from the issuance of our common stock through the exercise of options and warrants.

Edgar Filing: RadNet, Inc. - Form 10-Q

RECENT ACCOUNTING PRONOUNCEMENTS

In September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements," which defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. SFAS No. 157 applies under most other accounting pronouncements that require or permit fair value measurements and does not require any new fair value measurements. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007, and interim periods within those fiscal years, with earlier application encouraged. The provisions of SFAS No. 157 should be applied prospectively as of the beginning of the fiscal year in which the Statement is initially applied, except for a limited form of retrospective application for certain financial instruments. The Company will adopt this statement for fiscal year 2009. Management has not determined the effect the adoption of this statement will have on its consolidated financial position or results of operations.

In February 2007, the FASB issued SFAS No. 159, THE FAIR VALUE OPTION FOR FINANCIAL ASSETS AND FINANCIAL LIABILITIES, which permits entities to choose to measure many financial instruments and certain warranty and insurance contracts at fair value on a contract-by-contract basis. SFAS No. 159 is effective as of the beginning of an entity's first fiscal year that begins after November 15, 2007 (January 1, 2008 for calendar year-end companies). Management has not determined the effect the adoption of this statement will have on its consolidated financial position or results of operations.

25

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements reflect, among other things, management's current expectations and anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, or industry results, to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words "believes," "anticipates," "plans," "intends," "will," "expects," "should" and similar words and expressions are intended to identify forward-looking statements. Except as required under the federal securities laws or by the rules and regulations of the SEC, we assume no obligation to update any such forward-looking information to reflect actual results or changes in the factors affecting such forward-looking information. The factors included in "Risks Relating to Our Business," in our Annual Report on Form 10-K for the fiscal year ended October 31, 2006 and our Transition Report on Form 10-K/T for the two month transition period ended December 31, 2006, among others, could cause our actual results to differ materially from those expressed in, or implied by, the forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We sell our services exclusively in the United States and receive payment for our services exclusively in United States dollars. As a result, our financial results are unlikely to be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in foreign markets.

Edgar Filing: RadNet, Inc. - Form 10-Q

A large portion of our interest expense is not sensitive to changes in the general level of interest in the United States because the majority of our indebtedness has interest rates that were fixed when we entered into the note payable or capital lease obligation. On November 15, 2006, we entered into a \$405 million senior secured credit facility with GE Commercial Finance Healthcare Financial Services. This facility was used to finance our acquisition of Radiologix, refinance existing indebtedness, pay transaction costs and expenses relating to our acquisition of Radiologix, and to provide financing for working capital needs post-acquisition. The facility consists of a revolving credit facility of up to \$45 million, a \$225 million term loan and a \$135 million second lien term loan. The revolving credit facility has a term of five years, the term loan has a term of six years and the second lien term loan has a term of six and one-half years. Interest is payable on all loans initially at an Index Rate plus the Applicable Index Margin, as defined. The Index Rate is initially a floating rate equal to the higher of the rate quoted from time to time by The Wall Street Journal as the "base rate on corporate loans posted by at least 75% of the nation's largest 30 banks" or the Federal Funds Rate plus 50 basis points. The Applicable Index Margin on each the revolving credit facility and the term loan is 2% and on the second lien term loan is 6%. We may request that the interest rate instead be based on LIBOR plus the Applicable LIBOR Margin, which is 3.5% for the revolving credit facility and the term loan and 7.5% for the second lien term loan. The credit facility includes customary covenants for a facility of this type, including minimum fixed charge coverage ratio, maximum total leverage ratio, maximum senior leverage ratio, limitations on indebtedness, contingent obligations, liens, capital expenditures, lease obligations, mergers and acquisitions, asset sales, dividends and distributions, redemption or repurchase of equity interests, subordinated debt payments and modifications, loans and investments, transactions with affiliates, changes of control, and payment of consulting and management fees.

As part of the financing, we swapped at least 50% of the aggregate principal amount of the facilities to a floating rate within 90 days of the close of the agreement. On April 11, 2006, effective April 28, 2006, we entered into an interest rate swap on \$73.0 million fixing the LIBOR rate of interest at 5.47% for a period of three years. This swap was made in conjunction with the \$161.0 million credit facility closed on March 9, 2006. In addition, on November 15, 2006, we entered into an interest rate swap on \$107.0 million fixing the LIBOR rate of interest at 5.02% for a period of three years, and on November 28, 2006, we entered into an interest rate swap on \$90.0 million fixing the LIBOR rate of interest at 5.03% for a period of three years. Previously, the interest rate on the above \$270.0 million portion of the credit facility was based upon a spread over LIBOR which floated with market conditions.

In addition, our credit facility, classified as a long-term liability on our financial statements, is interest expense sensitive to changes in the general level of interest because it is based upon the current prime rate plus a factor.

ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this report, we performed an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). Based upon that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures are not effective in alerting them prior to the end of a reporting period to all material information required to be included in our periodic

filings with the SEC because we identified the following material weakness in the design of internal control over financial reporting: We concluded that we had insufficient processes to identify and resolve non-routine accounting matters, such as the identification of accrued liabilities associated with employee retention bonuses earned over specific time periods. The incorrect accounting for the foregoing was sufficient to lead management to conclude that a material weakness in the design of internal control over the accounting for non-routine transactions existed at September 30, 2007.

We determined to change the design of our internal controls over non-routine accounting matters by the identification of an outside resource at a recognized professional services company that we can consult with on non-routine transactions and the employment of qualified accounting personnel to deal with this issue together with the utilization of other senior corporate accounting staff, who are responsible for reviewing all non-routine matters and preparing formal reports on their conclusions, and conducting quarterly reviews and discussions of all non-routine accounting matters with our independent public accountants. We engaged MorganFranklin, a consulting firm with the requisite accounting expertise, to assist us, from time to time, in the evaluation and application of the appropriate accounting treatment, to provide support in the form of technical analysis related to accounting and financial reporting matters that may arise, and to provide management advice with respect to their preliminary conclusions regarding issues we wish to bring to their attention. To the extent our Chief Financial Officer identifies any non-routine accounting matters which require resolution, he will contact MorganFranklin and work closely with them, our audit committee and our auditors to resolve any issues. We are continuing to evaluate additional controls and procedures that we can implement and have added additional accounting personnel during fiscal 2007 to enhance our accounting processes and technical accounting resources. We do not anticipate that the cost of this remediation effort will be material to our financial statements. We believe that the engagement of MorganFranklin and use of their services should adequately address the identified weakness. With the acquisition of Radiologix we have added additional technical accounting staff from their organization which we believe will further reduce any material weakness.

It should be noted that any system of controls, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events.

PART II - OTHER INFORMATION

ITEM 1 LEGAL PROCEEDINGS

At September 30, 2007, the status of all current legal matters previously disclosed in Part 1, Item 3, of our Form 10-K/T for the two months ended December 31, 2006 and Part II, Item 1 of our Form 10-Q for the quarter ended June 30, 2007 is unchanged.

ITEM 1A RISK FACTORS

In addition to the other information set forth in this report, we urge you to carefully consider the factors discussed in Part I, "Item 1A Risk Factors" in our Form 10-K for the year ended October 31, 2006 and our Form 10-K/T for the two months ended December 31, 2006, which could materially affect

Edgar Filing: RadNet, Inc. - Form 10-Q

our business, financial condition and results of operations. The risks described in our Forms 10-K and 10-K/T are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

ITEM 6 EXHIBITS

The list of exhibits filed as part of this report is incorporated by reference to the Index to Exhibits at the end of this report.

27

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

RADNET, INC.

(Registrant)

Date: November 14, 2007

By /s/ Howard G. Berger, M.D.

Howard G. Berger, M.D., President,
Chief Executive Officer and Chairman
(Principal Executive Officer)

Date: November 14, 2007

By /s/ Mark D. Stolper

Mark D. Stolper, Chief Financial Officer
(Principal Financial and Accounting
Officer)

28

INDEX TO EXHIBITS

| EXHIBIT NUMBER ----- | DESCRIPTION ----- |
|----------------------------|--|
| 10.1 | Amendment No. 3 to Credit Agreement (1) |
| 10.2 | Amendment No. 3 to Second Lien Credit Agreement (2) |
| 31.1 | Certification of Howard G. Berger, M.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. * |
| 31.2 | Certification of Mark D. Stolper pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. * |

Edgar Filing: RadNet, Inc. - Form 10-Q

- 32.1 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 of Howard G. Berger, M.D. *
- 32.2 Certification Pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002 of Mark D. Stolper *

* Filed herewith.

- (1) Incorporated by reference to exhibit 99.1 filed with Form 8-K for August 24, 2007.
- (2) Incorporated by reference to exhibit 99.2 filed with Form 8-K for August 24, 2007.